Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PT-3902
- Development stage
- Preclinical
- Lead developer
- Path Therapeutics
- Modality
- Small Molecules
01
Overview
PT-3902 is a selective allosteric inhibitor of cAMP-specific 3',5'-cyclic phosphodiesterase 4B (PDE4B) being developed by Path Therapeutics as a potential anti-seizure treatment for Dravet Syndrome. Discovered using the MitoREAD machine-learning-derived screening platform, PT-3902 was synthesized de novo to target a novel allosteric binding pocket within the PDE4 active site. In vitro assays show that PT-3902 inhibits PDE4B with an IC50 of 27 nM and exhibits a 200-fold selectivity for PDE4B over PDE4D. This subtype selectivity is designed to offer improved tolerability compared to traditional pan-PDE4 inhibitors, which are often limited by dose-dependent adverse effects like nausea and emesis.
02
Targets
PDE4B (3',5'-cyclic-AMP phosphodiesterase 4B)
Beyond the preview
Go deeper on PT-3902.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PT-3902.